Organization | IBSA Institut Biochimique SA

IBSA Institut Biochimique SA Report issue

For profit Phase 2 Phase 3 Phase 4

Founded: Lugano Switzerland (1945)

Status: No NME R&D (1945)

Organization Overview

First Clinical Trial

2001

NCT00464607

First Marketed Drug

2006

levothyroxine (Synthroid)

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

IBSA Farmaceutici Italia Srl | IBSA Head of R&D Scientific Affairs | IBSA INST BIO | IBSA Institut Biochimique SA | INST BIOCHEM | INST BIOCHIMIQUE SA | INSTITUT BIOCHIMIQUE

Active Ingredients

Marketed Drugs (3)

diclofenac (voltaren) (2018)

levothyroxine (Synthroid) (2006)

lidocaine (xylocaine) (2020)

Drugs in Phase 4 Trials (8)

chondroitin sulfate (bovine) (1 trial)

diclofenac (voltaren) (5 trials)

follitropin alfa (Gonal-F) (5 trials)

hyaluronic acid (1 trial)

levothyroxine (Synthroid) (2 trials)

nitrofurantoin (furadantin) (1 trial)

urofollitropin (Metrodin) (2 trials)

water (1 trial)

Drugs in Phase 3 Trials (8)

celecoxib (celebrex) (1 trial)

chondroitin (3 trials)

ganirelix (1 trial)

human choriogonadotropin alfa (hCG) (2 trials)

menopausal gonadotropin (2 trials)

progesterone (progestasert) (9 trials)

sildenafil (viagra) (1 trial)

triptorelin (Trelstar) (1 trial)

Drugs in Phase 2 Trials (1)

selenomethionine se-75 (1 trial)

Drugs in Other Trials (3)

iron (2 trials)

salvia (1 trial)

sucrosomial iron (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Abortion, Threatened (Phase 3)

Athletic Injuries (Phase 4)

Hypothyroidism (Phase 4)

Infertility (Phase 4)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Soft Tissue Injuries (Phase 4)

Thyroiditis (Phase 2)

Thyroiditis, Autoimmune (Phase 2)

Toothache (Phase 3)

Wounds and Injuries (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 35
# of Trial APIs: 20